Brainstorm cell therapeutics regains compliance with nasdaq minimum bid price requirement

New york , oct. 30, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on october 29, 2024, the company received written notice from the nasdaq stock market stating that the company has regained compliance with the minimum closing bid price requirement under nasdaq listing rule 5550(a)(2) for continued listing on the nasdaq capital market. accordingly, the company's common stock will continue to trade on the nasdaq capital market, subject to the company's compliance with nasdaq's continued listing requirements.
BCLI Ratings Summary
BCLI Quant Ranking